Q-omics provides the consensus-scored ETDA profile across patient tissues and cancer cell-line models. ETDA expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, ETDA is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, ETDA RNA expression shows 6,827 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight TGCT, KIRC, and THYM as cancer lineages where ETDA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ETDA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ETDA survival associations across molecular data types. ETDA RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ETDA RNA expression–survival associations across cancer types. High ETDA expression shows unfavorable associations in TGCT, DLBC, LIHC, BLCA and COAD, but favorable associations in MESO. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for ETDA RNA expression.
This table summarizes ETDA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ETDA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ETDA shows higher tumor expression in KIRC, THCA, BRCA, KIRP, COAD and KICH. The KIRC box plot shows higher ETDA RNA expression in tumor versus normal tissue (log2 FC = +0.057, t-test p < 0.001).
This table shows molecular features associated with ETDA in patient tissues and cancer cell lines. In patient samples, ETDA shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
